A
Agilent Technologies, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.3% ·
share flow +0.1% ·
net new positions -5.6%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 166 | +3 | 195.92M | $26.03B | +9 | −5 |
| Q1 2026 | 165 | -3 | 181.10M | $20.68B | +3 | −7 |
| Q4 2025 | 167 | +1 | 200.20M | $27.23B | +3 | −1 |
| Q3 2025 | 22 | +2 | 109.95M | $14.10B | +3 | −2 |
| Q2 2025 | 18 | -1 | 102.37M | $12.08B | — | −1 |
| Q1 2025 | 16 | -1 | 41.13M | $4.81B | — | −1 |
| Q4 2024 | 17 | +1 | 41.24M | $5.54B | +2 | −1 |
| Q3 2024 | 15 | -1 | 26.67M | $3.96B | +1 | −2 |
| Q2 2024 | 16 | — | 29.82M | $3.86B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 34.00M | — | $4.01B | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 25.89M | — | $3.06B | 0.1% | n/c | 1 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passive) | 12.45M | -1.2% | $1.47B | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.95M | +0.2% | $1.06B | 0.2% | ▲ Add | 5 | SEC ↗ ×8 |
| 5 | Geode Capital Management ✦ (passive) | 7.32M | +1.6% | $860.14M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 3.35M | -2.1% | $395.09M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 2.04M | +424.1% | $240.96M | 0.2% | ▲ Add | 5 | SEC ↗ ×7 |
| 8 | Citadel Advisors ✦ | 1.65M | -21.4% | $194.47M | 0.2% | ▼ Trim | 5 | SEC ↗ ×2 |
| 9 | PRIMECAP Management ✦ | 1.53M | -0.4% | $180.69M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Marshall Wace ✦ | 1.51M | +2.9% | $178.33M | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Fidelity (FMR) ✦ | 1.21M | — | $142.78M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 1.10M | -42.5% | $129.36M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 481.20K | -8.8% | $56.79M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 451.79K | +9.9% | $53.32M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 221.99K | +472.6% | $26.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 184.73K | -28.2% | $21.80M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 20.55K | -92.2% | $2.43M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 18 | Gotham Asset Management ✦ | 12.01K | +171.4% | $1.42M | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $8.20M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,065 holders, 251.21M shares, $26.86B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 634 sh · $95,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology